Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GoodRx

GoodRx CEO says successful leadership is about more than staying calm through chaos: It’s about bosses reclaiming control

The post‑pandemic pendulum swung too far in employees’ favor, warns GoodRx’s Wendy Barnes—and business leaders need to build resilient teams that execute under pressure.

Fortune

I’m the CEO of GoodRx. A new era of access demands smarter design for direct-to-consumer drug pricing

A Fortune Most Powerful Women member, Barnes believes there are three essential elements for effective DTC models.

Fortune

Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers

Hims Hers Health Inc (NYSE:HIMS) investors can’t catch a break. Less than two months since Novo Nordisk AS (NYSE:NVO) terminated its Wegovy partnership with the telehealth company abruptly, the pharma giant is again in the news, this time partnering with GoodRx Holdings Inc (NASDAQ:GDRX) to provide discounted access to Ozempic…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

GoodRx (GDRX) Stock Is Sliding Tuesday: What's Going On?

GoodRx Holdings Inc (NASDAQ:GDRX) shares are pulling back Tuesday morning, as investors potentially take profits following Monday’s surge. The stock had jumped over 30% Monday after the company announced a new partnership with Novo Nordisk to expand access to popular GLP-1 medications.

Benzinga

How GoodRx CEO Wendy Barnes is trying to halve the cost of GLP-1 obesity drugs

Also: All the news and watercooler chat from Fortune.

Fortune

GoodRx Holdings Surges 5% After Hours on Novo Nordisk Partnership for $499 Monthly Ozempic, Wegovy Access

GoodRx Holdings Inc. (NASDAQ:GDRX) shares jumped 5.08% in after-hours trading on Monday, following the announcement of a collaboration with Novo Nordisk A/S (NYSE:NVO) to offer discounted GLP-1 medications at fixed pricing nationwide.

Benzinga

GoodRx Is Soaring on a Novo Nordisk Deal. Should You Buy GDRX Stock Here?

GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX shares into the strength before they crash again.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Novo Nordisk slashes price of Ozempic in half to $499 for cash-paying, eligible U.S. patients

The previous out-of-pocket price was nearly $1,000.

Fortune

Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets

GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of Ozempic (semaglutide) and Wegovy (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx, effective immediately.

Benzinga

Woman donates plasma for ‘extra money.’ Then she issues a warning about the unexpected side effect she’s experiencing

Donating plasma is one of the lesser known ways people can make some extra money without doing much. You just show up at a donation center, endure the prick of a needle, and collect some cash at the end.

The Mary Sue

If you have Medicare, here’s what you’ll pay for health care in 2025

The most significant Medicare change for 2025 will be the new $2,000 cap for prescription drugs.

Fortune

How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals

GoodRx's latest research shows surging demand for weight loss medications like Wegovy and Zepbound, despite high costs and limited insurance coverage, with consumers overspending $200 million in 2024.

Benzinga

Charter Names Simon Cassels SVP, Chief Creative Officer

Cassels’ award-winning accomplishments include Apple’s “Shot on iPhone” campaign

TV Tech

Take a Mid-Year Review of Your Health Insurance Coverage

Whether it's monitoring your deductible or using a health savings account, here are the best ways to maximize use of your health insurance coverage

Kiplinger

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

3 Top Stocks Under $10 to Buy Instead of GameStop

Meme stocks such as GME and AMC have risen substantially this month. However, due to their weak fundamentals, these companies are high-risk investments.

Top News

Sempre Health's innovative approach improves medication adherence and lowers costs

Initiatives like GoodRx and Sempre Health are working towards transparency and affordability in the drug supply chain to improve medication adherence. Blue...

WEKU

Flovent — a common asthma inhaler — will be discontinued in 2024. There will be a generic version available, but the change could make it hard for some patients to get their medication.

Kiplinger

Walgreens Launches Digital Tool To Help Save On Prescription Costs

Walgreens says its Rx Savings Finder will help customers compare coupon prices to get the best deal.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Free prescription discount cards from GoodRx — What’s the catch?

GoodRx’s prescription savings program offers significant discounts on prescription drugs, but not without some catches

Barchart

3 Hot Stocks Under $10 for Your September Watchlist

These outperformers are all trading under $10 per share - for now. After beating the S&P 500 year-to-date, analysts think these standout single-digit stocks all have room to keep running higher.

Fortune

A fertility app with lots of leaks

The agency says the fertility app Premom deceived users about their data.

Fortune

Mark Cuban has been taking on the drug industry. But which one?

The billionaire entrepreneur is making waves with his new drug company. But his generics aren’t always the lowest-priced deal.

Los Angeles Times

Editorial: FTC crackdown on GoodRx sends a message that private consumer data must be protected

Since 2017, GoodRx has helped millions of people find deals on prescription drugs via an app and website. But what its customers may not have known is that the Santa Monica-based health company had also been sharing information about their prescriptions and illnesses with third parties such as Google and…

The Independent UK

FTC fines GoodRx for unauthorized sharing of health data

The Federal Trade Commission has imposed a $1.5 million penalty on telehealth and prescription drug discount provider GoodRx Holdings Inc. for sharing users’ personal health data with Facebook, Google and other third parties without their consent

Chicago Sun-Times

Discount prescription company GoodRx fined $1.5 million for sharing sensitive user info

The FTC alleged the company shared info on users’ medication and illnesses for the purpose of targeted ads.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.